Bio-Techne Announced That Its Spatial Biology Brands, Lunaphore And Advanced Cell Diagnostics, Will Launch The First Fully Automated Spatial Multiomics Workflow With Same-section Hyperplex Detection Of RNA And Protein Biomarkers
Portfolio Pulse from Benzinga Newsdesk
Bio-Techne announced the launch of the first fully automated spatial multiomics workflow, enabling hyperplex detection of RNA and protein biomarkers on the same section. This innovative application, involving its brands Lunaphore and Advanced Cell Diagnostics, is set to be commercially available in Q2 2024.

January 25, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Techne's upcoming launch of a fully automated spatial multiomics workflow represents a significant advancement in the field of biomarker detection, potentially boosting the company's product offering and market position.
The announcement of a new product launch, especially one that is the first of its kind in the market, is typically seen as positive news for a company. It suggests innovation and expansion of the company's product line, which can lead to increased sales and market share. As the parent company, Bio-Techne is directly involved, and the impact on its stock is likely to be positive in the short term as investors may anticipate future revenue growth from this new offering.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100